US › Healthcare

Biomarin Pharmaceutical Inc (BMRN)

US · Healthcare · Biotechnology

$60.72+1.21%
Last close · 2026-08-04

Latest quarter · ended 2026-03-31

Revenue
$766.2M
Revenue YoY
+2.8%
Net profit
$105.5M
Profit YoY
-43.2%
EPS
$0.76
EPS estimate
$0.91
Net margin
13.8%

EPS came in at 0.76 against a street estimate of 0.91 — a miss of 16.5%.

Key statistics

Market cap
$11.60B
P/E
43.2
Forward P/E
12.1
P/B
1.87
Book value
$32.14
EPS (TTM)
$1.39
52-week high
$66.28
52-week low
$49.26
50-day MA
$57.28
200-day MA
$56.29
Beta
0.23

Analyst view

Analysts rate Biomarin Pharmaceutical Inc a buy (23 buy, 6 hold, 0 sell out of 29) with an average price target of $87.92.

Shareholding

Insiders
0.35%
Institutions
102.29%

Largest institutional holders

FundStake
BlackRock Inc10.25%
Vanguard Group Inc9.38%
Dodge & Cox7.53%
PRIMECAP Management Company7.34%
Vanguard Capital Management, LLC4.47%
Vanguard Portfolio Management, LLC4.29%
AQR Capital Management LLC3.97%
NORGES BANK3.90%

See the full picture

Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Biomarin Pharmaceutical Inc — free to start.

Google PlayApp Store

Other Healthcare companies

Eli Lilly and CompanyJohnson & JohnsonAbbVie IncUnitedHealth Group IncorporatedMerck & Company IncNovartis AG ADRAstraZeneca PLCThermo Fisher Scientific IncNovo Nordisk A/SAmgen IncAbbott LaboratoriesGilead Sciences Inc

Data updated 2026-08-05.